Roche: new approval for Ventana test in US
(CercleFinance.com) - Roche announced on Monday that it has received FDA approval for its Ventana PD-L1 test as a companion diagnostic to identify people with non-small cell lung cancer who are eligible for Libtayo, the immunotherapy developed by Sanofi and Regeneron.
The Swiss company said the approval will enable US physicians to offer their patients more personalised medicine and more effective management.
This approval will help physicians make more confident treatment decisions by identifying individuals whose tumors are likely to respond favourably to Libtayo immunotherapy, Roche said.
Lung cancer is the deadliest cancer in the world, with 2.2 million individuals diagnosed each year, the great majority of whom (85%) have "non-small cell" lung cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The Swiss company said the approval will enable US physicians to offer their patients more personalised medicine and more effective management.
This approval will help physicians make more confident treatment decisions by identifying individuals whose tumors are likely to respond favourably to Libtayo immunotherapy, Roche said.
Lung cancer is the deadliest cancer in the world, with 2.2 million individuals diagnosed each year, the great majority of whom (85%) have "non-small cell" lung cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.